CTMX insider transaction filings
CytomX Therapeutics, Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen CTMX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Carvajal Alejandra — Chief Legal Officer | Grant/award (A): 100,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Fuchs Charles S. — Director | Grant/award (A): 118,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Su Zhen — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Young Matthew P. — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Mohindru Mani — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Gilbert Halley E — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Ashworth Alan — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Meyers James R — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Jones Elaine V — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Ogden Christopher — Chief Financial Officer | Sale (S): 1,624 @ $3.05 | EDGAR |
| 2026-03-19 | 4 | Chu Yu-Waye — Chief Medical Officer | Sale (S): 21,279 @ $6.42 | EDGAR |
| 2026-03-19 | 4 | McCarthy Sean A. — CEO, Director | Sale (S): 118,969 @ $6.42 | EDGAR |
| 2026-03-19 | 4 | BELVIN MARCIA — SVP, Chief Scientific Officer | Sale (S): 31,492 @ $6.42 | EDGAR |
| 2026-03-19 | 4 | Ogden Christopher — Chief Financial Officer | Sale (S): 19,323 @ $6.42 | EDGAR |
| 2026-02-04 | 4 | Lester Rachael — Chief Business Officer | Grant/award (A): 20,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Chu Yu-Waye — Chief Medical Officer | Grant/award (A): 75,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | BELVIN MARCIA — SVP, Chief Scientific Officer | Grant/award (A): 60,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ogden Christopher — Chief Financial Officer | Grant/award (A): 90,000 @ $0 · Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | McCarthy Sean A. — CEO, Director | Grant/award (A): 210,000 @ $0 · Grant/award (A): 980,000 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | McCarthy Sean A. — CEO, Director | Sale (S): 101,793 @ $4.54 | EDGAR |
| 2025-10-29 | 4 | Lester Rachael — Chief Business Officer | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | McCarthy Sean A. — CEO, Director | Grant/award (A): 570,000 (derivative) @ $0 · Grant/award (A): 285,000 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Chu Yu-Waye — Chief Medical Officer | Grant/award (A): 87,500 (derivative) @ $0 · Grant/award (A): 43,750 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Ogden Christopher — Chief Financial Officer | Grant/award (A): 78,250 (derivative) @ $0 · Grant/award (A): 39,150 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | BELVIN MARCIA — SVP, Chief Scientific Officer | Grant/award (A): 36,300 (derivative) @ $0 · Grant/award (A): 18,150 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Ogden Christopher — Chief Financial Officer | Sale (S): 1,641 @ $2.95 · Option exercise (M): 37,500 @ $0 · Sale (S): 10,614 @ $2.69 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | BELVIN MARCIA — SVP, Chief Scientific Officer | Option exercise (M): 37,500 @ $0 · Sale (S): 13,884 @ $2.69 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | McCarthy Sean A. — CEO, Director | Option exercise (M): 150,000 @ $0 · Sale (S): 55,511 @ $2.69 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Su Zhen — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Young Matthew P. — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Mohindru Mani — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Gilbert Halley E — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Ashworth Alan — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Meyers James R — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Jones Elaine V — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | BELVIN MARCIA — SVP, Chief Scientific Officer | Sale (S): 19,512 @ $0.60 | EDGAR |
| 2025-03-20 | 4 | McCarthy Sean A. — CEO, Director | Sale (S): 37,656 @ $0.60 | EDGAR |
| 2025-03-20 | 4 | Ogden Christopher — Chief Financial Officer | Sale (S): 8,551 @ $0.60 | EDGAR |
| 2025-03-20 | 4 | Chu Yu-Waye — Chief Medical Officer | Sale (S): 4,025 @ $0.60 | EDGAR |
| 2025-03-20 | 4 | ROWLAND LLOYD A — General Counsel | Sale (S): 10,203 @ $0.60 | EDGAR |
| 2025-02-10 | 4/A | BELVIN MARCIA — SVP, Chief Scientific Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 57,500 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | BELVIN MARCIA — SVP, Chief Scientific Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 57,500 @ $0 · Grant/award (A): 140,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Chu Yu-Waye — Chief Medical Officer | Grant/award (A): 56,000 @ $0 · Grant/award (A): 57,500 @ $0 · Grant/award (A): 238,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Ogden Christopher — Chief Financial Officer | Grant/award (A): 44,000 @ $0 · Grant/award (A): 57,500 @ $0 · Grant/award (A): 225,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | McCarthy Sean A. — CEO, Director | Grant/award (A): 180,000 @ $0 · Grant/award (A): 195,000 @ $0 · Grant/award (A): 800,000 (derivative) @ $0 · Grant/award (A): 390,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CytomX Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CTMX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →